Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON43325
NL-OMON43325
Completed
Not Applicable

*Sound-Ear-Check*: analysis and validation of screening tests for hearing using non-speech sounds in noise. - Validity of Sound-Ear-Check (SEC) as a hearing screening method.

Academisch Medisch Centrum0 sites104 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Academisch Medisch Centrum
Enrollment
104
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Group I: Aged \>18 years old
  • •Group II: children 6\-12 years old
  • •Normal hearing ability (hearing threshold levels at octave frequencies \*20 dB HL) or mild to moderate sensorineural hearing loss)
  • •Native speaker

Exclusion Criteria

  • •Language problems
  • •Conductive hearing loss, as expressed by an air\-bone gap \> 15 dB HL

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Study of neonatal screening for hearing loss using otoacoustic emissions
CTRI/2023/07/055805Jagjivan Ram Railway Hospital
Completed
Not Applicable
Development and verification of a binaural loudness-based first-fit procedurehearing-impairmentreduced dynamic range10019243
NL-OMON46206Academisch Medisch Centrum20
Not yet recruiting
Not Applicable
Development of speech test in Kannada language
CTRI/2023/02/049816akshmanabharathi R
Recruiting
Not Applicable
Checking the effectiveness of a new hearing assessment (Oto-acoustic Emission) in identifying hearing loss caused due to Cisplatin (widely used as part of cancer treatment) in adult cancer patients.Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx
CTRI/2023/12/060500Tata Research Administrative Council
Recruiting
Not Applicable
Checking the feasibility of a new hearing assessment tool(Oto-acoustic Emission) in identifying early and significant amount of hearing loss caused due to Cisplatin (widely used as a chemotherapy drug in cancer patients) chemotherapy in pediatric cancer patients.
CTRI/2023/03/051221Tata Research Administrative Council